Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 6c
May 13, 2020 7:06 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.81), $0.06 worse than the analyst estimate of ($0.75).
Despite these unprecedented times, the first quarter was a period of important progress for Fulcrum and the fundamentals of our business remain strong, said Robert J. Gould, Ph.D.,... More
